Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098553 | 0.93 | POLB (0.40) | GRM1MALT1MEN1KMT2AAPP | |
| SCHEMBL4093068 | 0.88 | GRM1 (0.38) | GRM1KDM4ENPSR1MEN1KMT2A | |
| SCHEMBL2235793 | 0.87 | MEN1 (0.39) | GRM1KDM4ENPSR1MALT1MEN1 | |
| SCHEMBL4083548 | 0.86 | GRM1 (0.43) | GRM1KDM4ENPSR1MALT1MEN1 | |
| SCHEMBL2236075 | 0.85 | GRM1 (0.47) | GRM1KDM4ENPSR1MALT1MEN1 | |
| SCHEMBL2232303 | 0.85 | PDE4B (0.37) | GRM1KDM4EMALT1MEN1KMT2A | |
| SCHEMBL2232507 | 0.85 | NPBWR1 (0.42) | GRM1KDM4EMALT1MEN1KMT2A | |
| SCHEMBL11908071 | 0.84 | GRM1 (0.40) | GRM1KDM4ENPSR1MALT1MEN1 | |
| SCHEMBL2237067 | 0.82 | GRM1 (0.41) | GRM1KDM4ENPSR1MALT1MEN1 | |
| SCHEMBL2234987 | 0.82 | GRM1 (0.43) | GRM1KDM4ENPSR1MALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | claimed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008024438-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | GRM1 239/4885KDM4E 3449/4885NPSR1 219/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | GRM1 239/4885KDM4E 3449/4885NPSR1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.